These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 11400001)

  • 1. Homocysteinaemia in HIV-infected patients treated with highly active antiretroviral therapy.
    Bernasconi E; Uhr M; Magenta L; Ranno A; Telenti A;
    AIDS; 2001 May; 15(8):1081-2. PubMed ID: 11400001
    [No Abstract]   [Full Text] [Related]  

  • 2. Metabolic disorders and cardiovascular risk in HIV-infected patients treated with antiretroviral agents.
    Fantoni M; Del Borgo C; Autore C; Barbaro G
    Ital Heart J; 2002 May; 3(5):294-9. PubMed ID: 12066561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of metabolic abnormalities in patients infected with HIV receiving antiretroviral therapy that contains lopinavir-ritonavir.
    Martínez E; Domingo P; Galindo MJ; Milinkovic A; Arroyo JA; Baldovi F; Larrousse M; León A; de Lazzari E; Gatell JM
    Clin Infect Dis; 2004 Apr; 38(7):1017-23. PubMed ID: 15034836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk factors for sexual and erectile dysfunction in HIV-infected men: the role of protease inhibitors.
    Moreno-Pérez O; Escoín C; Serna-Candel C; Picó A; Alfayate R; Merino E; Reus S; Boix V; Sanchez-Paya J; Portilla J
    AIDS; 2010 Jan; 24(2):255-64. PubMed ID: 19915446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of highly active antiretroviral therapy associated metabolic abnormalities and lipodystrophy in HIV infected patients.
    Feleke Y; Fekade D; Mezegebu Y
    Ethiop Med J; 2012 Jul; 50(3):221-30. PubMed ID: 23409405
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship between low bone mineral density and highly active antiretroviral therapy including protease inhibitors in HIV-infected patients.
    Fernández-Rivera J; García R; Lozano F; Macías J; García-García JA; Mira JA; Corzo JE; Gómez-Mateos J; Rueda A; Sánchez-Burson J; Pineda JA
    HIV Clin Trials; 2003; 4(5):337-46. PubMed ID: 14583850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic disorders in a cohort of patients treated with highly aggressive antiretroviral therapies during primary HIV-1 infection.
    Capiluppi B; Ciuffreda D; Sciandra M; Marroni M; Tambussi G; Lazzarin A
    AIDS; 2000 Aug; 14(12):1861-2. PubMed ID: 10985329
    [No Abstract]   [Full Text] [Related]  

  • 8. [Hypertension, HIV infection, and highly active antiretroviral therapy].
    Bernardino de la Serna JI; Zamora FX; Montes ML; García-Puig J; Arribas JR
    Enferm Infecc Microbiol Clin; 2010 Jan; 28(1):32-7. PubMed ID: 19409669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical outcome after coronary events in patients treated with HIV-protease inhibitors.
    Monsuez JJ; Gallet B; Escaut L; Vayre F; Charniot JC; Pulik M; Merad M; Minozzi C; Slama M; Weber S; Vittecoq D
    Eur Heart J; 2000 Dec; 21(24):2079-80. PubMed ID: 11102259
    [No Abstract]   [Full Text] [Related]  

  • 10. Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study.
    Martinez E; Mocroft A; García-Viejo MA; Pérez-Cuevas JB; Blanco JL; Mallolas J; Bianchi L; Conget I; Blanch J; Phillips A; Gatell JM
    Lancet; 2001 Feb; 357(9256):592-8. PubMed ID: 11558485
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 'Do HIV-infected injecting drug users over-report adherence to highly active antiretroviral therapy?' A comparison between patients' self-reports and serum protease inhibitor concentrations in the French Manif 2000 cohort study.
    Duran S; Solas C; Spire B; Carrieri MP; Fuzibet JG; Costagliola D; Lacarelle B; Moatti JP;
    AIDS; 2001 May; 15(8):1075-7. PubMed ID: 11399998
    [No Abstract]   [Full Text] [Related]  

  • 12. Impact of atazanavir-based HAART regimen on the carotid intima-media thickness of HIV-infected persons: a comparative prospective cohort.
    de Saint-Martin L; Bressollette L; Perfezou P; Bellein V; Ansart S; Vallet S; Pasquier E
    AIDS; 2010 Nov; 24(18):2797-801. PubMed ID: 21063175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The burden of metabolic diseases amongst HIV positive patients on HAART attending The Johannesburg Hospital.
    Julius H; Basu D; Ricci E; Wing J; Basu JK; Pocaterra D; Bonfanti P
    Curr HIV Res; 2011 Jun; 9(4):247-52. PubMed ID: 21631427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study.
    Friis-Møller N; Weber R; Reiss P; Thiébaut R; Kirk O; d'Arminio Monforte A; Pradier C; Morfeldt L; Mateu S; Law M; El-Sadr W; De Wit S; Sabin CA; Phillips AN; Lundgren JD;
    AIDS; 2003 May; 17(8):1179-93. PubMed ID: 12819520
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipodystrophy, metabolic disorders, and human immunodeficiency virus infection: Aquitaine Cohort, France, 1999. Groupe d'Epidémiologie Clinique du Syndrome d'Immunodéficience Acquise en Aquitaine.
    Thiébaut R; Daucourt V; Mercié P; Ekouévi DK; Malvy D; Morlat P; Dupon M; Neau D; Farbos S; Marimoutou C; Dabis F
    Clin Infect Dis; 2000 Dec; 31(6):1482-7. PubMed ID: 11096016
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disorders of iron metabolism associated with protease inhibitor therapy.
    McNabb JC; Cappa JA; Ross JW
    Clin Infect Dis; 2001 Aug; 33(3):413-4. PubMed ID: 11438916
    [No Abstract]   [Full Text] [Related]  

  • 17. Effects of sex and race on lipodystrophy pathogenesis.
    Nolan D; Mallal S
    J HIV Ther; 2001 May; 6(2):32-6. PubMed ID: 11501201
    [No Abstract]   [Full Text] [Related]  

  • 18. Comparison of the risks of atherosclerotic events versus death from other causes associated with antiretroviral use.
    Kwong GP; Ghani AC; Rode RA; Bartley LM; Cowling BJ; da Silva B; Donnelly CA; van Sighem AI; Cameron DW; Danner SA; de Wolf F; Anderson RM
    AIDS; 2006 Oct; 20(15):1941-50. PubMed ID: 16988515
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Epidemiology of the metabolic abnormalities in patients with HIV infections].
    Mehta R; Loredo B; Sañudo ME; Hernandez-Jiménez S; Rodríguez-Carranza SI; Gómez-Pérez FJ; Rull JA; Aguilar-Salinas CA
    Rev Invest Clin; 2004; 56(2):209-21. PubMed ID: 15377074
    [TBL] [Abstract][Full Text] [Related]  

  • 20. C-Reactive protein levels over time and cardiovascular risk in HIV-infected individuals suppressed on an indinavir-based regimen: AIDS Clinical Trials Group 5056s.
    Henry K; Kitch D; Dube M; Zackin R; Parker RA; Sprecher D; Hammer S; Currier J;
    AIDS; 2004 Dec; 18(18):2434-7. PubMed ID: 15622323
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.